-

About FDA

The Office of the Commissioner (OC)

2010 Preceptors


Gardner

John W. Gardner, M.D., Dr.P.H. 

Office of Information Management, OC
Rockville, MD

Background

M.S., Physical Chemistry & Biochemistry, Brigham Young University
M.P.H., Epidemiology & Biostatistics, Harvard University
M.D., University of Utah
Dr.P.H., Epidemiology & Biostatistics, Harvard University
FDA Experience - 5 years

 

Research Interests

Data systems for epidemiologic research and regulatory purposes to enhance public health and protection.

Proposed Research Project for FDA Commissioner’s Fellow

This project would be for a Commissioner’s Fellow to work on medical informatics, learning about the integrative scientific computing issues encountered by FDA data systems.  There are many aspects of FDA system integration and scientific computing efforts, which are all open to the Fellow for project development. A key FDA integrative data concept is called the JANUS Data Model, which is intended to house all FDA structured data (according to data standards, eg, Health Level Seven). This would include clinical and non-clinical study data, adverse event reports, facility registrations, and product listings, among others. The concept of the JANUS data model is to manage structured data at multiple levels – Exchange (eg, receive and validate HL7 messages), Persistence (extract, transform, load and store transactional data), Data Management (user-friendly interoperable data repositories), Data Mart and Special Purposes (data organized for specific analytic and/or review use), Analysis (tools for review and analysis), and Results (outputs of analyses). The Fellow would work with FDA business and IT professionals in integration efforts on projects such as developing, testing, and implementing the JANUS data model, defining its benefits and risks, and exploring and evaluating its utilization for various specific purposes.  There are also several other enterprise IT development programs available for project work, focusing on interoperability and central management of integrated data and on utilization of external data sources and large data sets. 

Select Recent Publications

Gardner JW: Fatal Pneumococcal Meningitis: Failure of Acute Care Focus of Medical Practice. Military Medicine, Aug 2007; 172(8): 902-905. 

(Contributing Editor):  Force Health Protection.  Vision Document, Offices of the Joint Chiefs of Staff and Secretary of Defense, 2003, 53 pages. 

Scoville SL, Gardner JW, Magill AJ, Potter RN, Kark JA: Nontraumatic Deaths during U.S. Armed Forces Basic Training, 1977-2001. Am J Prev Med, 2004; 26(3): 205-212.

Scoville SL, Gardner JW, Potter RN: Traumatic Deaths during U. S. Armed Forces Basic Training, 1977-2001. Am J Prev Med, 2004; 26(3): 194-204.

Gardner JW, Kark JA:  Clinical Diagnosis, Management and Surveillance of Exertional Heat Illness. In: Pandolf KB, Burr RE, eds. Medical Aspects of Harsh Environments, Volume 1, 2001: ch 7, pp 231-280. 

Gardner JW, Gibbons RV, Hooper TI, Cunnion SO, Kroenke K, Gackstetter GD:  Identifying new diseases and their causes:  The dilemma of illnesses in Gulf War veterans. Military Medicine, Mar 2003; 168: 186-193. 

Potter RN, Gardner JW, Deuster PA, Jenkins P, McKee K Jr, Jones BH:  Musculoskeletal Injuries in an Army Airborne Population.  Military Medicine, Dec 2002; 167: 1033-1040. 

Gutmann FD, Gardner JW, Potter RN, Kark JA:  Nontraumatic Exercise-related Deaths in the U. S. Military, 1996-1999.  Military Medicine, Dec 2002; 167: 964-970.

Gardner JW:  Death by Water Intoxication.  Military Medicine, May 2002; 167: 432-434.

Gardner JW, Cozzini CB, Kelley PW, Kark JA, Peterson MR, Gackstetter GD, Spencer JD:  The Department of Defense Medical Mortality Registry.  Military Medicine, 2000; 165, Suppl. 2: 57-61. 

Gardner JW, Schuman KL, Slattery ML, Sanborn JS, Abbott TM, Overall JC Jr: Is Vaginal Douching Related to Cervical Carcinoma?  Am J Epidemiol,  Feb 1991; 133: 368-375.

 

Top of page


RNelson

 Robert M. Nelson, M.D., Ph.D.

Pediatric Ethicist

Office of Pediatric Therapeutics

Office of the Commissioner (OC)

Rockville, MD

Background

B.A. - Wesleyan University

M.D.- Yale University School of Medicine

M.Div. - Yale Divinity School

Ph.D.- Harvard University

FDA Experience – 3 Years

Research Interests

My research has focused on two broad areas of pediatric research ethics:  the ethical aspects of pediatric clinical investigations involving FDA regulated products, and empirical investigations into different aspects of parent and child decision-making concerning research participation. At FDA, specific areas of interest include ethical aspects of different trial designs, the choice of control groups (including placebo controls), the use of animal models, the assessment of research risks and the possibility of direct benefit, and ethical aspects of international pediatric research. My academic research has focused on risk perception, voluntary choice, and the balancing of risks and potential benefits in making a decision about the design of clinical trials. My academic research has been funded by the Greenwall Foundation, the National Science Foundation, and the National Institutes of Health.

Proposed Research Project for FDA Commissioner’s Fellow

The FDA Commissioner’s Fellow participating in this research program will be exposed to all aspects of FDA oversight of pediatric product development, including drugs, biologics and devices. More specifically, the Fellow will be able to observe, discuss and analyze the ethical aspects of pediatric product development. The Fellow will be able to select a more focused project on some aspect of pediatric research ethics, and have access to the necessary FDA resources. Pediatric research is increasingly international with working relationships between FDA and other international regulatory authorities. This offers an opportunity for a Fellow to explore the ethical issues raised by multi-national pediatric research involving both developed and developing countries.

Project Requirements

M.D. and/or Ph.D. in a relevant discipline.  Ideally, the candidate will have some experience in health policy, legislation or law, along with a familiarity with the ethics and regulation of human subjects protections.

Select Recent Publications

Miller VA, Reynolds WW, Ittenbach RF, Luce MF, Beauchamp TL, Nelson RM. Challenges in measuring a new construct: perception of voluntariness for research and treatment decision making. J Empir Res Hum Res Ethics. 2009 Sep;4(3):21-31.

Hoehn KS, Nathan A, White LE, Ittenbach RF, Reynolds WW, Gaynor JW, Wernovsky G, Nicolson S, Nelson RM. Parental perception of time and decision-making in neonatal research. J Perinatol. 2009 Jul;29(7):508-11.

Reynolds WW, Nelson RM. Empirical data and the acceptability of research risk: a commentary on the charitable participation standard. Arch Pediatr Adolesc Med. 2008 Jan;162(1):88-90.

Morris MC, Besner D, Vazquez H, Nelson RM, Fischbach RL. Parental opinions about clinical research. J Pediatr. 2007 Nov;151(5):532-7, 537.e1-5.       

Nelson RM: Minimal Risk, Yet Again. Journal of Pediatrics. 150(6): 570-72, 2007.

Bagley SJ, Reynolds WW, and Nelson RM: Is a “Wage-Payment” Model for Research Participation Appropriate for Children? Pediatrics. 119(1): 46-51, 2007.

Reynolds WW, Nelson RM. Risk perception and decision processes underlying informed consent to research participation. Soc Sci Med. 2007 Nov;65(10):2105-15.

Morris MC, Nelson RM. Randomized, controlled trials as minimal risk: an ethical analysis. Crit Care Med. 2007 Mar;35(3):940-4.

Baer GR and Nelson RM: Ethical Challenges in Neonatal Research: Summary Report of the Ethics Group of the Newborn Drug Development Initiative. Clinical Therapeutics. 28(9): 1399-1407, 2006.

Pulsipher MA, Nagler A, Iannone R, and Nelson RM: Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 46(4):422-33, 2006.

 

Top of page


Rodriguez

 William J. Rodriguez, M.D., Ph.D.

Office of Pediatric Therapeutics

Office of the Commissioner (OC)

White Oak/Silver Spring, MD

Background

B.S. , Ph.D, M.D. - Georgetown University

FDA Experience – 9 Years

 

Research Interests

The interest of this researcher has previously included the areas of new antibiotic development, the treatment of middle ear infections, and the study of monoclonal antibodies in the prevention and treatment of respiratory syncytial virus in infants and young children.  More recently, he has participated in the pediatric initiatives which have encouraged pediatric drug development. Information from some of the initiatives’ early findings has been communicated in scientific journals. However, a wealth of data remains currently available for extraction and analysis at the FDA on drugs studied in pediatrics. The studies could be converted into data bases accessible for analysis in a variety ways and to address a variety of questions. We plan a novel program, that would include assigning a researcher in the program to work on areas of significant public health, mine and manage data currently available in the pediatric domain, conduct scientific analysis and develop pertinent research under the direction of the appropriate FDA supervisor(s).

Proposed Research Project for FDA Commissioner’s Fellow

The FDA Commisisoner’s Fellow participating in this research program will master approaches to exploring unique areas of pediatric drug development, explore the differences between issued study requests from the agency and the studies actually submitted by the sponsors, areas of pediatric exposure-response relationships, issues in pediatric endpoints and product safety and pediatric formulation considerations.The Fellow could analyze the differences in outcomes by drugs and drug classes and the relationship to study design. Amongst others, they will explore advanced topics in clinical pharmacology, including exposure-response relationships, biomarkers, utilization of clinical trial simulations (optimizing clinical trial designs) and modeling to predict study outcomes and identify key covariates for pediatric dosing recommendations. Future directions include identification of approaches that improve the possibilities of successful trial design in pediatrics, as well as defining economic benefits of drugs or classes of drugs which have been recently labeled  as result of the pediatric initiatives under FDAMA, BPCA, PPREA, and FDAAA.

Select Recent Publications

Improving Pediatric Dosing Through Pediatric Initiatives – What We Have Learned William Rodriguez, M.D., Ph.D.; Arzu Selen, Ph.D.; Debbie Avant, R.Ph.; Chandra Chaurasia, Ph.D.; Terrie Crescenzi, R.Ph.; Gerlie Gieser, Ph.D.; Jennifer Di Giacinto, Pharm.D.; Shiew-Mei Huang, Ph.D.;  Peter Lee, Ph.D.; Lisa Mathis, M.D.; Dianne Murphy, M.D.; Shirley Murphy, M.D.; Rosemary Roberts, M.D.; Hari Cheryl Sachs, M.D.; Sandra Suarez, Ph.D.; Veneeta Tandon, Ph.D.; and Ramana S. Uppoor, Ph.D.   Pediatrics 2008;121:530-539

More Appropriate Clinical Trial Design for Drug Labels. McCunne S, Mathis L,Cochetto D, Ball S and Rodriguez W. Safer,Better, Drug Information.Journal .2006;40:185-195

Criteria Supporting the Study of Drugs in the Newborn. Ward R, Benitz E, Benjamin D. Blackmon L., Giacoia G.,Huddack M., Lasky T.,   Rodriguez W and Selen A. Clinical Therapeutics 2006;28:1385-1398

Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity P. Brian Smith, MD, MHS, Daniel K. Benjamin, Jr., MD, PhD, MPH M. Dianne Murphy, MD, Rosemary Johann-Liang, MD, Solomon Iyasu, MD, Robert M. Califf, MD, Jennifer S. Li, MD, MHS, and William Rodriguez, MD, PhD Pediatrics, Sept. 2008, Vol. 122, Issue 3. e 628-633

Amoxicillin For Post-Exposure Inhalational Anthrax (Peia) In Pediatrics: Rationale For Dosing Recommendations J. J. Alexander M.D., MPH.; P. M. Colangelo PharmD, Ph.D.,; C. K. Cooper M.D.; R. Roberts M.D.; W. J. Rodriguez M.D.; D. Murphy M.D Pediatric Infectious Disease Journal, Volume 27, No. 11, November 2008

 

Top of page


 

 

 

 

 

    
-
-
  • Share  Email this Page
-
-
-